Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

On October 23, 2024 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported the upcoming presentation of new preclinical data supporting the combination of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 with targeted therapies, including KRASG12C inhibitors and pan-RAS inhibitors, at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (Press release, Kura Oncology, OCT 23, 2024, View Source [SID1234647338]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting an update to our growing body of preclinical and clinical data that demonstrate the potential of KO-2806 as a companion therapeutic to augment the antitumor activities of KRASG12C and pan-RAS inhibitors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "These findings support the promising therapeutic strategy of blunting the effects of innate and adaptive resistance to targeted agents to treat cancers driven by KRAS mutations, including KRASG12C non-small cell lung cancer (NSCLC) and KRAS-mutant colorectal cancers. If successful, we believe KO-2806 could drive enhanced antitumor activity and become a combination partner to multiple targeted therapies in large solid tumor indications."

Details for the session titles and information for the two abstracts are listed below. Copies of the presentations will be available in the Posters and Presentations section on Kura’s website following presentation at the conference.

KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
Session Date and Time: Friday, October 25, 2024; 9:00 AM – 3:00 PM ET
Session and Location: Drug Resistance and Modifiers, Exhibition Hall
Poster Number: PB376

The next-generation farnesyl transferase inhibitor KO-2806 sensitizes colorectal cancers to pan-RAS inhibition
Session Date and Time: Friday, October 25, 2024; 9:00 AM – 3:00 PM ET
Session and Location: Drug Resistance and Modifiers, Exhibition Hall
Poster Number: PB378

About KO-2806

KO-2806 is a next-generation inhibitor of farnesyl transferase designed to improve upon the potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates. At the 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), Kura presented preclinical data supporting the rationale for combining KO-2806 with distinct classes of targeted therapies, including tyrosine kinase inhibitors, KRASG12C inhibitors and KRASG12D inhibitors. Kura is evaluating KO-2806 in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy, in combination with cabozantinib in clear cell renal cell carcinoma and in combination with adagrasib in KRASG12C NSCLC. Additional information about clinical trials for KO-2806 can be found at View Source

Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

On October 23, 2024 Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, reported the publication of data supporting the continued clinical development and intravenous route of administration of NG-350A, its lead program for the treatment of advanced metastatic cancers (Press release, Akamis Bio, OCT 23, 2024, View Source [SID1234647354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NG-350A is a next-generation transgene-armed tumor gene therapy designed to drive intratumoral expression of a CD40 agonist monoclonal antibody resulting from selective replication in both primary and metastatic epithelial-derived solid tumors. Data from the first-in-human dose escalation FORTITUDE study in patients with metastatic/advanced epithelial tumors supports proof-of-mechanism for NG-350A, with strong evidence of tumor-selective delivery, replication and transgene expression. Additionally, this study demonstrates that intravenous delivery of NG-350A results in a superior overall pharmacokinetic and pharmacodynamic profile, with no apparent disadvantages versus intratumoral injection.

Blood sample analysis from patients showed sustained persistence of NG-350A up to seven weeks after intravenous dosing was completed (maximum follow up), particularly at higher dose levels. Further, a dose-dependent pattern was also seen with systemic delivery, resulting in four patients remaining positive for vector DNA in biopsies nearly two months after receiving the treatment. Transgene messenger RNA from replicating NG-350A was detected in nearly half the patients with intravenous treatment but only in one patient that had received intratumoral injection. Sustained increases in inflammatory cytokines were also observed following dosing, particularly with higher intravenous dose levels.

"These findings are highly supportive of our ongoing focus on intravenous administration of NG-350A to safely drive sustained transgene expression within the tumor microenvironment. Systemic delivery offers considerable advantages over current intratumoral approaches, particularly with transgene-containing viral vectors where the cargo needs to reach both the primary tumor and metastases throughout the body – an application for which direct injection or dependence on an abscopal effect is not viable," said Oliver Rosen, M.D., Chief Medical Officer at Akamis.

Dr. Rosen continued: "This study demonstrated that a T-SIGn therapeutic armed with targeted immunostimulatory proteins such as CD-40 agonists can be successfully delivered intravenously, resulting in a superior overall pharmacokinetic and pharmacodynamic profile compared to intratumoral administration. Our preliminary data suggest that the local expression of immunostimulatory therapies following intravenous administration can overcome toxicity that limits non-targeted systemic administration. We look forward to continuing to understand the potential of this treatment in upcoming proof-of-concept studies."

NG-350A will now be studied in combination with chemoradiotherapy in FORTRESS, a multicenter open-label non-randomized Phase 1b trial of patients with locally advanced rectal cancer.

A link to the publication "First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments" can be found here.

About T-SIGn

Akamis Bio’s T-SIGn therapeutics are based on a replication competent, chimeric group B adenovirus backbone which has been adapted via directed evolution to home specifically to both primary and metastatic epithelial-derived solid tumor tissue following intravenous delivery. Once at the tumor site, T-SIGn therapeutics can drive the intratumoral expression of multiple transgene payloads, turning solid tumor cells into "drug factories" while leaving healthy tissue unaltered and intact. The intratumoral expression of immunologically active biomolecules and therapeutic proteins can result in the remodeling of the solid tumor microenvironment, triggering robust antitumor immune responses. T-SIGn therapeutics have the potential to be used in the monotherapy setting, as well as in combination with other immuno-oncology agents to target the key mechanisms that tumors use to evade the immune system.

Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium

On October 23, 2024 Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, reported that it is presenting preclinical data on its new development candidate, NTX-452, a novel Werner syndrome helicase (WRN) inhibitor, at the 36th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024 in Barcelona, Spain (Press release, Nimbus Therapeutics, OCT 23, 2024, View Source [SID1234647339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

WRN is a helicase required for DNA replication and DNA repair and is a validated target for tumors with microsatellite instability (MSI). MSI is a phenotypic consequence of defective mismatch repair (dMMR) and occurs in various tumor types, including colorectal, gastric and endometrial cancers. Inhibition of WRN activity has the potential to induce synthetic lethality in MSI-high (MSI-H) tumors. Using a structure-based drug design approach, Nimbus developed highly potent and selective covalent and non-covalent inhibitors of WRN, and has selected a novel non-covalent inhibitor, NTX-452, as the clinical candidate.

In a poster (abstract #356) titled "Preclinical Characterization of NTX-452, a Potent, Selective and Highly Efficacious WRN Inhibitor for the Treatment of MSI-H Tumors," Nimbus is presenting new data from preclinical assays and several tumor models that support the potential of the company’s non-covalent WRN inhibitor as a treatment for MSI-H tumors.

Key findings from the preclinical studies include:

NTX-452 demonstrated potent and selective inhibition of WRN activity with favorable drug-like properties.
The compound showed synthetic lethality in MSI-H tumor cells, triggering a DNA damage response that suppressed cell viability and promoted cell death.
Treatment with NTX-452 at low doses in vivo exhibited a robust pharmacodynamic response, resulting in tumor regression across multiple MSI-H cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) tumor models, including established models for colorectal, gastric and endometrial cancers.
Significant tumor regression and complete responses were observed at low oral doses in MSI-H models refractory to immunotherapy and chemotherapy.
"These compelling preclinical results for NTX-452 further highlight the significant potential of our WRN inhibitor as a promising therapeutic approach for patients with MSI-H tumors, many of whom fail to respond to or eventually relapse with current standard of care therapies including immune checkpoint inhibitors," said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. "Our novel non-covalent approach to WRN inhibition, coupled with the robust efficacy demonstrated across diverse tumor types and treatment settings, positions our program for potential best-in-class status. We are particularly encouraged by the low doses required to achieve robust anti-tumor activity in preclinical models, which may translate to an improved benefit-risk profile in the clinic."

The preclinical profile of NTX-452 suggests several potential advantages in the treatment of MSI-H tumors, including:

The non-covalent mechanism may offer more durable on-target activity, and a greater safety window compared to covalent inhibitors.
High potency and favorable pharmacokinetic properties indicate the potential for target levels of efficacy at lower doses.
Broad efficacy across treatment-naïve, chemotherapy-pretreated, and immunotherapy-pretreated models suggests potential utility in both early-stage and advanced disease settings.
Activity in multiple MSI-H tumor types, including those with diverse genetic alterations, indicates potential broad applicability across dMMR/MSI-H cancers.
Nimbus is advancing NTX-452 with plans to enter the clinic in the first half of 2025.

TreeFrog Therapeutics Enters Into Pioneering Research Collaboration in Immuno-Oncology With the University of Pittsburgh

On October 23, 2024 TreeFrog Therapeutics reported a research collaboration with the University of Pittsburgh focused on the potential of tertiary lymphoid structures (TLS) in immuno-oncology, an exciting emerging field in cancer research (Press release, TreeFrog Therapeutics, OCT 23, 2024, View Source [SID1234647355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Harnessing the pioneering research ongoing by Tullia Bruno, Ph.D, Assistant Professor in the Department of Immunology at the University of Pittsburgh and her team at UPMC Hillman Cancer Center, alongside the biotechnology expertise of TreeFrog Therapeutics and its proprietary C-Stem 3D cell encapsulation technology, the collaboration aims to break new ground in 3D immunology.

Tertiary lymphoid structures are ectopic lymphoid structures that develop in chronically infected organs, sites of inflammation, autoimmune diseases, and in transplants subjected to chronic rejection. In recent years, they have been described in solid tumors, where they act as crucial players in the body’s immune response to cancer. By deciphering the intricate mechanisms underlying TLS function and leveraging this knowledge, researchers aim to develop novel treatment approaches that harness the immune system’s inherent capacity to recognize and eliminate cancer cells.

"We are delighted to embark on this collaboration with Professor Bruno to apply our encapsulation technology to further understand and work with TLS, bringing new levels of control over the microenvironment of these amazing 3D immune structures. Research indicates that the presence of TLS in cancer may boost anti-tumor immunity and improve responses and prognosis, so I am excited to work with Professor Bruno and her team to explore synergies and opportunities of our 3D technology in this emerging field" said Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

"If we are able to recapitulate TLS using 3D technology, there are so many questions we could ask about their formation and modulation in a controlled manner. With 3D technology being a new frontier, this could help immensely as we work to better understand TLS biology, which could complement our work in patient samples and physiologically relevant murine models," commented Professor Bruno, Assistant Professor, Department of Immunology, University of Pittsburgh.

Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform

On October 23, 2024 Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, reported that it has received initial results from the proprietary Deep Docking AI platform (Press release, Rakovina Therapeutics, OCT 23, 2024, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-initial-drug-candidates-from-deep-docking-ai-molecule-discovery-platform [SID1234647340]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rakovina employed the Deep Docking algorithm to evaluate billions of molecular structures to develop a short-list of drug candidates that have been optimized to a specific target-product profile. A screening effort of this magnitude would not be possible with traditional medicinal chemistry approaches.

"With the Deep Docking AI platform, these initial results were achieved in less than five months versus traditional methods of discovery which would take thousands of years," said Rakovina Therapeutics Executive Chairman Jeffrey Bacha. "AI dramatically increases speed and the likelihood of success of our drug discovery platform," he added.

"We are pleased to receive this short-list of recommended drug candidates from our initial AI screening effort," said Bacha. "Our excitement is similar to receiving a core sample from a promising mining project, but instead of rare metals, this sample contains a curated list of potential novel best-in-class drug candidates that could provide significant improvements in the treatment of cancer for patients worldwide."

Selected drug candidates will be synthesized for validation in Rakovina Therapeutics’ laboratories at the University of British Columbia during the coming months with the goal of advancing a best-in-class DDR drug candidate to human clinical trials in collaboration with pharmaceutical company partners.

In March 2024, the Company announced that it was entering into a collaboration agreement with Dr. Artem Cherkasov, granting Rakovina Therapeutics exclusive access to the Deep Docking AI Platform for DNA-damage response targets. Dr. Cherkasov is a professor at the University of British Columbia (UBC) and a senior scientist at the Vancouver Prostate Centre. These results are the initial output of the ongoing collaboration.

The goal of the collaboration is to leverage AI algorithms to analyze billions of potential drug candidates, with the goal of accelerating discoveries, reducing costs, and improving the success rate in identifying best-in-class drug candidates in the DNA-damage response field. The agreement provides Rakovina with ownership rights to all novel drug candidates generated through the collaboration.

Rakovina Therapeutics will present the initial results of this research in a poster presentation at the Society for Neuro-Oncology Annual Meeting, which is being held November 21 through 24, 2024, at the George R. Brown Convention Center in Houston, Texas.

Additionally, in Sept. 2024, the Company announced an agreement with Variational AI of Vancouver to leverage the capabilities of the Enki AI platform which has been trained to identify novel inhibitors of specific kinase targets in the DDR field. Rakovina Therapeutics expects initial results from this research in the next several months.